Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 2/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | PDE4A | P27815 | 4/20 | 0.32 |
| ▸ | PDE4B | Q07343 | 4/20 | 0.32 |
| ▸ | PDE4C | Q08493 | 4/20 | 0.32 |
| ▸ | PDE4D | Q08499 | 4/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10029184 | 1.00 | ACHE (0.33) | ACHECA1CA2PDE4APDE4B | |
| SCHEMBL15580978 | 0.89 | ACHE (0.33) | ACHECA1CA2PDE4APDE4B | |
| SCHEMBL16229259 | 0.89 | PDE4B (0.39) | ACHECA1CA2PDE4APDE4B | |
| SCHEMBL12934644 | 0.89 | PDE4B (0.39) | ACHECA1CA2PDE4APDE4B | |
| SCHEMBL10029179 | 0.88 | PDE4B (0.39) | ACHECA1CA2PDE4APDE4B | |
| SCHEMBL701629 | 0.88 | PDE4B (0.39) | ACHECA1CA2PDE4APDE4B | |
| SCHEMBL15580960 | 0.82 | PDE4B (0.47) | ACHECA1CA2PDE4APDE4B | |
| SCHEMBL10029176 | 0.82 | PDE4B (0.38) | ACHECA1CA2PDE4APDE4B | |
| SCHEMBL10029173 | 0.82 | PDE4B (0.38) | ACHECA1CA2PDE4APDE4B | |
| SCHEMBL10029181 | 0.81 | PDE4B (0.44) | ACHECA1CA2PDE4APDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8124646-B2 | Substituted isoindoline-1,3-dione derivatives | CONCERT PHARMACEUTICALS, INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-20100324108-A1 | SUBSTITUTED ISOINDOLINE-1,3-DIONE DERIVATIVES | CONCERT PHARMACEUTICALS INC. | 2010-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324108-A1 | SUBSTITUTED ISOINDOLINE-1,3-DIONE DERIVATIVES | QDPR, IDO1, ADRA1D | ACHE 462/4885CA1 4145/4885CA2 1325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.